如何在高危急性髓系白血病中应用抢先性过继细胞免疫治疗
异基因造血干细胞移植是高危急性白血病潜在治愈手段,但复发仍是主要死因。供者淋巴细胞输注可恢复移植物抗白血病免疫监视,对慢性期慢性髓系白血病疗效显著,对复发急性髓系白血病和急性淋巴细胞白血病缓解率较有限。本文讨论在检测到可测量残留病或混合嵌合体时抢先输注供者淋巴细胞的证据、其他缓解后细胞治疗及决策框架。
要点
- 供者淋巴细胞输注对慢性期慢性髓系白血病疗效显著,对复发急性髓系白血病和急性淋巴细胞白血病缓解率较有限。
- 抢先性供者淋巴细胞输注的证据来自少数多为单中心回顾性非随机研究,结果令人鼓舞。
- 本文提供实践框架以支持临床医生考虑抢先性细胞治疗时的决策。
核心结论
- 抢先性供者淋巴细胞输注预防高危急性白血病移植后复发的证据令人鼓舞,但仅来自少数多为单中心回顾性非随机研究。
研究设计与样本
- 本文为综述,讨论抢先性过继细胞免疫治疗的现有证据、其他缓解后细胞治疗及临床决策框架。
主要发现
- 异基因造血干细胞移植是高危急性白血病的潜在治愈手段,但疾病复发仍是这些患者的主要死因。
- 供者淋巴细胞输注可恢复移植物抗白血病免疫监视,但疗效因血液系统疾病类型而异。
- 慢性期移植的复发慢性髓系白血病对供者淋巴细胞输注非常敏感,而复发急性髓系白血病和急性淋巴细胞白血病的缓解率较有限。
- 多个研究组探索在检测到可测量残留病或混合嵌合体时抢先输注供者淋巴细胞以预防即将发生的复发。
临床怎么用
- 本文提供实践框架,以支持临床医生在为这一难治患者群体考虑抢先性细胞治疗时的决策过程。
局限性
- 支持抢先性供者淋巴细胞输注策略有效性的证据仅来自少数研究,且多为单中心回顾性非随机研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for patients with high-risk acute leukemias, but unfortunately disease recurrence remains the major cause of death in these patients. Infusion of donor lymphocytes (DLI) has the potential to restore graft-versus-leukemia immunologic surveillance; however, efficacy varies across different hematologic entities. Although relapsed chronic myeloid leukemia, transplanted in chronic phase, has proven remarkably susceptible to DLI, response rates are more modest for relapsed acute myeloid leukemia and acute lymphoblastic leukemia. To prevent impending relapse, a number of groups have explored administering DLI preemptively on detection of measurable residual disease (MRD) or mixed chimerism. Evidence for the effectiveness of this strategy, although encouraging, comes from only a few, mostly single-center retrospective, nonrandomized studies. This article seeks to (1) discuss the available evidence supporting this approach while highlighting some of the inherent challenges of MRD-triggered treatment decisions post-transplant, (2) portray other forms of postremission cellular therapies, including the role of next-generation target-specific immunotherapies, and (3) provide a practical framework to support clinicians in their decision-making process when considering preemptive cellular therapy for this difficult-to-treat patient population.
引用
- Biederstädt A, Rezvani K. How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy. Blood. 2023. PMID: 35512203. doi:10.1182/blood.2021012411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。